Early Treatment of Demyelination Events Cuts Long-Term Disability in MS
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
THURSDAY, July 20, 2023 -- For multiple sclerosis patients with a first demyelinating event, earlier treatment initiation is associated with a reduction in the risk for long-term disability, according to a study published online July 19 in Neurology.
Alvaro Cobo-Calvo, M.D., Ph.D., from Hospital Universitari Vall d'Hebron in Barcelona, Spain, and colleagues examined the association between receiving very early treatment and the risk for long-term disability, including a five-point magnetic resonance score (MRS), in patients with a first demyelinating event. Data were included for 580 patients who received at least one disease-modifying drug (DMD). Participants were classified into tertiles according to the time from first demyelinating event to first DMD: first tertile (six months; 194 patients); second tertile (6.1 to 16 months; 192 patients); and third tertile (16.1 months onward; 194 patients).
The researchers found that compared with patients in the third tertile, very early treatment reduced the risk for reaching Expanded Disability Status Scale 3.0, secondary progressive multiple sclerosis, and sustained disease progression at 12 months after treatment initiation (hazard ratios, 0.55, 0.40, and 0.50, respectively). Compared with patients in the third tertile, those in the first tertile had a lower disability progression rate (β estimate, −0.009) and a lower severe disability measured by the Patient Determined Disease Steps (β estimate, −0.52). A 62.4 percent reduction was seen in the median time between the first demyelinating event and the first-ever treatment initiation from patients displaying a raw MRS1 to patients with a raw MRS5.
"Altogether, our results support the robustness and effectiveness of very early treatment to halt long-term disability progression, and stress that earlier detection and treatment is encouraged," Cobo-Calvo said in a statement.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
Mortality in Rheumatic Heart Disease Is High
FRIDAY, June 7, 2024 -- Mortality related to rheumatic heart disease (RHD) is high and is correlated with the severity of valve disease, according to a study published online June...
Higher County-Level Prostate Cancer Screening Tied to Better Outcomes
FRIDAY, June 7, 2024 -- Higher county-level prevalence of prostate-specific antigen (PSA) screening is associated with lower odds of advanced disease, all-cause mortality, and...
Metabolic Impact on Offspring Similar for Frozen, Fresh Embryo Transfer
FRIDAY, June 7, 2024 -- For glucose and lipid profiles during early childhood, the impact of frozen embryo transfer (FET) is comparable to that of fresh embryo transfer, according...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.